In this article, we will take a look at the Billionaire Larry Robbins’ 10 Dividend Stock Picks.
Taking the stage at the 2026 Sohn New York Conference, the Founder and CEO of Glenview Capital Management wasted little time setting the stage. He pointed to an unusual market dynamic. While 41 stocks in the S&P 500 had doubled over the past year, nearly one-third of the index remained in negative territory despite the market being up 30%. Robbins titled his presentation “Double Down” and laid out nine investment ideas in about ten minutes.
He divided the market into five categories. Among stocks that have fallen, he identified companies that have clearly stumbled, companies that have not yet stumbled but appear headed for trouble, and the category Glenview focuses on: resilient businesses that investors believe face existential threats that, in his view, do not actually exist.
Among stocks that have doubled, Glenview remains interested in companies benefiting from AI infrastructure trends and rapidly improving fundamentals. The firm also looks at former fallen angels whose valuations still appear attractive even after strong rallies. Using that framework, Robbins highlighted nine ideas spread across three groups: down but coiled spring, doubled with huge momentum, and doubled and still cheap.
On May 21, Glenview Capital reported that following healthy Q1 results and increased annual guidance, it reduced its overall holdings by 3.75 million shares. The firm said the move was consistent with its diversification parameters and was intended to create buying power for additional opportunities in what it described as a volatile macro environment.
Despite the reduction, CVS Health remains one of Glenview’s three largest positions. The firm said it has no plans to make further adjustments to its CVS holdings and continues to have strong confidence in the company’s near-, medium-, and long-term outlook.
Given this, we will take a look at Larry Robbins’ top dividend stocks.
Larry Robbins of Glenview Capital
Our Methodology
For this list, we scanned Glenview Capital’s 13F portfolio as of Q1 2026 and identified dividend stocks from there. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Bio-Techne Corporation (NASDAQ:TECH)
Glenview Capital’s Stake Value: $9,736,665
On June 11, Piper Sandler initiated coverage of Bio-Techne Corporation (NASDAQ:TECH) with a Neutral rating and a $65 price target. The firm began coverage of the life science tools sector with what it described as a “feet in the shallow end of the pool” approach. Among the companies under coverage, Piper only recommends buying Twist Bioscience, citing its increasing exposure to next-generation drug discovery and development.
According to the analyst, headwinds tied to biotech and academic spending, along with China-related exposure, are likely to improve in the near term. Even so, Piper wants to see some of the sector’s next major growth drivers take shape before becoming more constructive on additional stocks.
The firm argues that investors “can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-COVID.”
Bio-Techne Corporation (NASDAQ:TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
9. Baker Hughes Company (NASDAQ:BKR)
Glenview Capital’s Stake Value: $18,539,359
On June 3, Citi lowered its price recommendation on Baker Hughes Company (NASDAQ:BKR) to $74 from $80. It reiterated a Buy rating on the stock. The revision came as the firm updated its models for companies in the oil and gas equipment and services sector.
During the Q1 2026 earnings call, Chairman, President, and CEO Lorenzo Simonelli said Baker Hughes continued to reshape its portfolio through a series of strategic transactions. He noted that the company had announced the divestiture of Waygate Technologies. Combined with the sale of PSI to Crane and the joint venture with Cactus, Baker Hughes expects these moves to generate about $3 billion in gross proceeds during 2026.
Simonelli also highlighted strong demand across the Industrial & Energy Technology (IET) segment and said the company has gained greater visibility into future growth. IET bookings reached a record $4.9 billion during the quarter, resulting in a book-to-bill ratio of 1.5x. The segment’s remaining performance obligations (RPO) climbed to a record $33.1 billion. Simonelli added that management has become increasingly confident that its Horizon 2 IET order target will exceed $40 billion.
Executive Vice President and CFO Ahmed Moghal echoed those remarks, saying Baker Hughes delivered another quarter of strong order growth. Total company orders reached $8.2 billion in the first quarter, including $4.9 billion from the IET segment.
Baker Hughes Company (NASDAQ:BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide.
